Compare MakeMyTrip Ltd (MMYT) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Natera Inc. Common Stock — how do they compare? MakeMyTrip Ltd trades at $43.7 (market cap $4.21B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 13.5× MakeMyTrip Ltd's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Natera Inc. Common Stock for 0 Days on average.
| MMYT | NTRA | |
|---|---|---|
Market Cap | $4.21B | $57.03B |
Volume | 954,905 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.73 | $425.64 |
52-Week Low | $36.30 | $179.42 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $4.87B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $44.70, showing modest daily gains of 0.81%. The stock faces bearish technical signals with mixed earnings performance - beating Q1 2026 estimates but missing Q4 2025 and Q2 2026. Revenue growth remains positive with $978M in 2025, though profitability metrics show volatility. Analyst sentiment remains strongly bullish with a $77 consensus target representing 72% upside potential.
The stock presents significant upside based on analyst targets but faces execution risks amid volatile earnings and rising debt levels. Key catalysts include the planned Indian listing and operational resilience, while risks include geopolitical disruptions and competitive pressures in the travel sector.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
